NYSE · FMS
Healthcare · Medical - Care Facilities
$22.47
Down-$0.66 (-2.85%)
Updated Oct 31, 2026, 6:47 PM
SID Score
5.6/10
Composite research score
Smart Money
56/100
Neutral
Price performance · FMS
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
FMS closed at $22.47 after 21 trading sessions, up 0.99% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $22.82 | $22.89 | $22.445 | $22.47 | 967.97K |
| Oct 29, 2026 | $22.89 | $23.13 | $22.835 | $23.13 | 1.36M |
| Oct 28, 2026 | $22.46 | $22.70 | $22.445 | $22.62 | 803.02K |
| Oct 27, 2026 | $22.56 | $22.67 | $22.475 | $22.50 | 784.32K |
| Oct 26, 2026 | $22.75 | $22.9851 | $22.73 | $22.75 | 569.77K |
| Oct 23, 2026 | $22.42 | $22.73 | $22.27 | $22.68 | 733.46K |
| Oct 22, 2026 | $21.59 | $22.235 | $21.57 | $22.23 | 1.12M |
| Oct 21, 2026 | $21.53 | $21.67 | $21.45 | $21.56 | 1.26M |
| Oct 20, 2026 | $22.23 | $22.32 | $20.9101 | $21.41 | 6.21M |
| Oct 19, 2026 | $21.88 | $22.01 | $21.815 | $21.94 | 562.84K |
| Oct 16, 2026 | $22.28 | $22.38 | $22.105 | $22.17 | 620.94K |
| Oct 15, 2026 | $21.99 | $22.28 | $21.84 | $22.13 | 1.46M |
| Oct 14, 2026 | $21.22 | $21.59 | $21.14 | $21.54 | 1.21M |
| Oct 13, 2026 | $21.37 | $21.42 | $21.055 | $21.08 | 1.07M |
| Oct 12, 2026 | $21.24 | $21.34 | $21.125 | $21.21 | 692.12K |
| Oct 9, 2026 | $21.07 | $21.24 | $20.905 | $21.06 | 1.01M |
| Oct 8, 2026 | $20.28 | $20.89 | $20.23 | $20.88 | 1.47M |
| Oct 7, 2026 | $22.50 | $22.665 | $20.50 | $20.69 | 3.24M |
| Oct 6, 2026 | $22.63 | $22.645 | $22.415 | $22.42 | 652.47K |
| Oct 5, 2026 | $22.42 | $22.68 | $22.34 | $22.65 | 567.52K |
| Oct 2, 2026 | $22.14 | $22.29 | $22.09 | $22.25 | 478.55K |
The latest Smart Investors Daily articles mentioning FMS.
Company
Market Activity
Research & News
FMS research
Company profile and research snapshot.
Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 21, 2026 | BERENBERG | Buy | — |
| Sep 4, 2026 | ODDO BHF | Buy | — |
| Aug 31, 2026 | BNP PARIBAS | Underperform | — |
| Aug 31, 2026 | INTESA SANPAOLO EQUITY RESEARCH | Buy | — |
| Aug 28, 2026 | METZLER EQUITIES | Hold | — |
No generated briefing is available yet.
Benzinga · Oct 22, 2026
Expands access to Fresenius Medical Care's globally established portfolio of advanced kidney replacement therapies in the U.S.FDA clearance of multiFiltratePRO and approval of dedicated solutions expand continuous
Yahoo · Oct 21, 2026
Fresenius Medical Care, the world's leading provider of products and services for people with kidney disease, today announced the U.S. launch of the multiFiltratePRO System for critically ill patients with acute kidney injury (AKI). multiFiltratePRO's integrated technology eliminates the need for separate citrate and calcium pumps, and automatically adjusts as treatment conditions change, making complex treatment easier for hospital intensive care teams to manage.
Yahoo · Oct 19, 2026
Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, presents new research and evidence-driven innovations aimed at improving patient outcomes during the American Society of Nephrology's (ASN) Kidney Week 2026, taking place October 21-25 in Denver, Colorado.
Benzinga · Oct 12, 2026
Truist Securities analyst David Macdonald maintains Fresenius Medical Care (NYSE:FMS) with a Hold and lowers the price target from $25 to $24.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning FMS.
